Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer

PLoS ONE(2023)10.1371/journal.pone.0287151Source: DataRank Database

Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer is a research paper published in PLoS ONE (2023). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 0.41)OA: goldTopics (50)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Lisa Middleton,Jason M. Unrine ORCID,Shu Kwun Lui,Joseph Rollins,Emma Nienaber ORCID

Live enrichment

PubMed:37816015 PMC:PMC10564129 OpenAlex:https://openalex.org/W4387493082

Kentucky IDeA Networks of Biomedical Research Excellence

Grant: P20GMI04489

Kentucky IDeA Networks of Biomedical Research Excellence

Grant: P20GM103436

Foundation for the National Institutes of Health

Grant: U01 HL152392

National Institutes of Health

Grant: 1U01HL152392-01

Kentucky Network for Innovation & Commercialization (“KYNETIC”)

National Institutes of Health

Grant: 2P20GM103436-19

IDeA Networks of Biomedical Research Excellence in Kentucky

FWCI

0.41

Citation Percentile

0.7%

Citation Trend

2024

2025

goldLicense: cc-by

journalhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0287151&type=printable

publisherhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0287151&type=printable

publisherhttps://dx.plos.org/10.1371/journal.pone.0287151

journalhttps://doi.org/10.1371/journal.pone.0287151

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37816015

Fields of Study

Hypothalamic control of reproductive hormonesMetal complexes synthesis and propertiesReproductive Biology and Fertility03 medical and health sciences0302 clinical medicineFemaleHumansReceptors, LHRHTriple Negative Breast NeoplasmsCarboplatinPlatinumGonadotropin-Releasing HormoneCell Line, TumorAntineoplastic Agents

MeSH Terms

Antineoplastic AgentsFemaleHumansGonadotropin-Releasing HormonePlatinumReceptors, LHRHCarboplatinCell Line, TumorTriple Negative Breast Neoplasms

Keywords

CarboplatinIn vivoTriple-negative breast cancerBreast cancerOvarian cancerInternal medicinePharmacologyCancer researchChemistryCancerEndocrinologyMedicineBiologyChemotherapyCisplatinScienceQRTriple Negative Breast NeoplasmsAntineoplastic AgentsGonadotropin-Releasing HormoneCell Line, TumorHumansFemaleReceptors, LHRHResearch ArticlePlatinum

Sustainable Development Goals

SDG 0: Good health and well-being